Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AVXL
stocks logo

AVXL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
--
--
-0.110
-21.43%
--
--
-0.115
-11.54%
--
--
-0.125
-21.88%
Estimates Revision
The market is revising No Change the revenue expectations for Anavex Life Sciences Corp. (AVXL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -52.66%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-52.66%
In Past 3 Month
Wall Street analysts forecast AVXL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVXL is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast AVXL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVXL is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.450
sliders
Low
20.00
Averages
20.00
High
20.00
Current: 4.450
sliders
Low
20.00
Averages
20.00
High
20.00
H.C. Wainwright
Buy
downgrade
$42 -> $20
2025-11-19
Reason
H.C. Wainwright
Price Target
$42 -> $20
2025-11-19
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Anavex to $20 from $42 and keeps a Buy rating on the shares after blarcamesine received a negative trend opinion from European regulators. The firm cites the reduced probability of approval for blarcamesine in Europe for treatment of Alzheimer's disease for the target cut.
JonesResearch
Soumit Roy
Buy
to
Hold
downgrade
2025-10-23
Reason
JonesResearch
Soumit Roy
Price Target
2025-10-23
downgrade
Buy
to
Hold
Reason
JonesResearch analyst Soumit Roy downgraded Anavex to Hold from Buy without a price target. Anavex's valuation is entirely dependent on the decision from the European Medicines Agency regarding the approval of blarcamesine in Alzheimer's disease, the analyst tells investors in a research note. The firm sees the decision coming in Q1 of 2026. It cites Anavex's current valuation and potential downside on the news for the downgrade.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$42
2025-04-07
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$42
2025-04-07
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$46
2025-04-07
Reason
D. Boral Capital
Jason Kolbert
Price Target
$46
2025-04-07
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$42
2025-03-31
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$42
2025-03-31
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$42
2025-02-18
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$42
2025-02-18
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Anavex Life Sciences Corp (AVXL.O) is -9.27, compared to its 5-year average forward P/E of -15.65. For a more detailed relative valuation and DCF analysis to assess Anavex Life Sciences Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.65
Current PE
-9.27
Overvalued PE
-7.48
Undervalued PE
-23.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.66
Undervalued EV/EBITDA
-11.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
145.97
Current PS
0.00
Overvalued PS
562.15
Undervalued PS
-270.21
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AVXL News & Events

Events Timeline

(ET)
2025-11-25
07:32:52
Anavex projects more than three years of financial sustainability.
select
2025-11-25
07:32:24
Anavex announces Q4 earnings per share of 11 cents, below consensus estimate of 15 cents.
select
2025-11-14 (ET)
2025-11-14
07:35:51
Anavex to Seek Reassessment of CHMP Opinion on MAAA for Blarcamesine
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-04Businesswire
Anavex Life Sciences Faces Investigation After 35.9% Share Drop Following EMA Negative Vote
  • Legal Investigation Initiated: The Schall Law Firm is investigating Anavex Life Sciences Corp. for potential violations of securities laws, which could lead to significant losses for investors.
  • Stock Price Volatility: On November 14, 2025, Anavex shares plummeted over 35.9% after the European Medicines Agency (EMA) issued a negative trend vote on its marketing authorization application for blarcamesine, reflecting strong market concerns about the company's future.
  • Disclosure Issues: The investigation focuses on whether Anavex failed to disclose critical information pertinent to investors in a timely manner, potentially impacting shareholder investment decisions and confidence.
  • Investor Rights Protection: The Schall Law Firm is urging affected shareholders to participate in the lawsuit, emphasizing the company's responsibilities under securities law to protect investor rights.
[object Object]
Preview
9.5
12-03Benzinga
Marvell Reports Impressive Q3 Earnings, Alongside American Eagle, Microchip Technology, Box, and Other Major Stocks Rising on Wednesday

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining approximately 100 points on Wednesday.

  • Marvell Technology Earnings Report: Marvell Technology, Inc. reported better-than-expected third-quarter earnings, with adjusted earnings of 76 cents per share and revenue of $2.08 billion, leading to a 7.5% increase in its stock price.

  • Notable Stock Gains: Several companies saw significant stock price increases, including Ambitions Enterprise Management Co. (up 32%), MapLight Therapeutics, Inc. (up 23%), and Aeva Technologies, Inc. (up 19.9%).

  • Other Companies' Performance: American Eagle Outfitters, Inc. and Microchip Technology Incorporated also reported strong earnings, contributing to their respective stock price increases of 13.3% and 9.5%.

[object Object]
Preview
3.0
12-02Benzinga
Key Stocks Reporting Earnings This Week: Costco, MongoDB, Ulta, and Others

  • Upcoming Earnings Reports: Retail investors are anticipating a week of earnings reports from various companies, including MongoDB, CrowdStrike, and Salesforce, among others.

  • Analyst Expectations: Analysts have raised price targets for CrowdStrike ahead of its earnings report, with expectations of earnings of 94 cents per share and revenue of $1.21 billion.

  • Retail Sector Focus: Major retailers like Macy's and Dollar Tree are set to report earnings, with significant attention on their performance as the holiday season approaches.

  • Market Movements: The stock of Victoria's Secret is highlighted for its potential volatility, as over 20% of its shares are currently sold short, indicating investor caution.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Anavex Life Sciences Corp (AVXL) stock price today?

The current price of AVXL is 4.45 USD — it has decreased -2.63 % in the last trading day.

arrow icon

What is Anavex Life Sciences Corp (AVXL)'s business?

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.

arrow icon

What is the price predicton of AVXL Stock?

Wall Street analysts forecast AVXL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVXL is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Anavex Life Sciences Corp (AVXL)'s revenue for the last quarter?

Anavex Life Sciences Corp revenue for the last quarter amounts to -10.83M USD, decreased -20.13 % YoY.

arrow icon

What is Anavex Life Sciences Corp (AVXL)'s earnings per share (EPS) for the last quarter?

Anavex Life Sciences Corp. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Anavex Life Sciences Corp (AVXL)'s fundamentals?

The market is revising No Change the revenue expectations for Anavex Life Sciences Corp. (AVXL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -52.66%.
arrow icon

How many employees does Anavex Life Sciences Corp (AVXL). have?

Anavex Life Sciences Corp (AVXL) has 34 emplpoyees as of December 05 2025.

arrow icon

What is Anavex Life Sciences Corp (AVXL) market cap?

Today AVXL has the market capitalization of 397.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free